Cargando…
Chitosan Nanoparticles Strengthen Vγ9Vδ2 T-Cell Cytotoxicity Through Upregulation Of Killing Molecules And Cytoskeleton Polarization
BACKGROUND: During the past few years, immune cell therapy for malignant cancer has benefited a considerable amount of patients worldwide. As one of several promising candidates for immunotherapy, Vγ9Vδ2 γδ T cells have many unique biological advantages, such as non-MHC restriction and have been not...
Autores principales: | Lin, Li, He, Junyi, Li, Jiawei, Xu, Yan, Li, Jingxia, Wu, Yangzhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890518/ https://www.ncbi.nlm.nih.gov/pubmed/31819434 http://dx.doi.org/10.2147/IJN.S212898 |
Ejemplares similares
-
Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
por: Alnaggar, Mohammed, et al.
Publicado: (2019) -
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
por: Xu, Yan, et al.
Publicado: (2020) -
Combined killing of cancer cells and cross presentation of tumor antigen by Vγ9Vδ2 T cells
por: Olofsson, Gitte Holmen, et al.
Publicado: (2015) -
Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016) -
Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens
por: Holmen Olofsson, Gitte, et al.
Publicado: (2021)